Skip to main content
Clinical Trials/NCT01037816
NCT01037816
Completed
Phase 4

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of FS-67 Patches in Adolescent Subjects With Ankle Sprain

Hisamitsu Pharmaceutical Co., Inc.1 site in 1 country252 target enrollmentDecember 2009

Overview

Phase
Phase 4
Intervention
FS-67 Patch
Conditions
Ankle Sprain
Sponsor
Hisamitsu Pharmaceutical Co., Inc.
Enrollment
252
Locations
1
Primary Endpoint
Primary: Sum of Pain Intensity Difference (SPID) at 8-hours (SPID8) Upon Monopodal Weight Bearing.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The objective of this study is assess the efficacy and safety of single and multiple applications of the FS-67 patch in the treatment of ankle sprain in pediatric population (ages 13-17).

Detailed Description

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of FS-67 Patches in Adolescent Subjects With Ankle Sprain

Registry
clinicaltrials.gov
Start Date
December 2009
End Date
December 2010
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Grade 1 or Grade 2 ankle sprain

Exclusion Criteria

  • Pregnancy or lactation

Arms & Interventions

FS-67 patch

One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)

Intervention: FS-67 Patch

Placebo Patch

One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)

Intervention: Placebo Patch

Outcomes

Primary Outcomes

Primary: Sum of Pain Intensity Difference (SPID) at 8-hours (SPID8) Upon Monopodal Weight Bearing.

Time Frame: 8 hours of patch application on Day 1

Summed Pain Intensity Differences (SPID8) worst observation carried forward (WOCF) during monopodal weight-bearing on the affected ankle observed at specified time-points (1, 2, 4, 6, \& 8 hrs) after patch application. The SPID8 (WOCF) is a time-weighted sum of the pain intensity differences (PID), which were calculated as change from pain intensity at baseline to pain intensity at specified time points. Pain intensity was evaluated by means of a 100 mm visual analog scale (VAS), on which 0 mm represented no pain and 100 mm represented the worst pain imaginable. SPID8 was derived as the time-weighted sum (area under the curve) of the PID, where the weight assigned to each PID score is equal to the elapsed time (in hrs) since the previous scheduled evaluation time point. Five time-points were observed to calculate SPID8 therefore the potential SPID8 scores could range from -500 to +500 with negative values indicating increased pain over 8 hours.

Secondary Outcomes

  • Sum of Pain Intensity Difference at 8-hours (SPID8) at Rest.(8 hours of patch application on Day 1)

Study Sites (1)

Loading locations...

Similar Trials